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Sessa Stilhano0000-0000-0000-0000 ,III Rodrigo Portes Ureshino0000-0000-0000-0000 ,IV,V Luiz Felipe Pinho Moreira0000-0000-0000-0000 I
I Laboratorio de Cirurgia Cardiovascular e Fisiopatologia da Circulacao (LIM-11), Instituto do Coracao (InCor), Faculdade de Medicina FMUSP, Universidade
de Sao Paulo, Sao Paulo, SP, BR. II Instituto de Saude e Sociedade (ISS), Universidade Federal de Sao Paulo (UNIFESP), Santos, SP, BR. III Faculdade de Ciencias
Medicas da Santa Casa de Sao Paulo (FCMSCSP), Sao Paulo, SP, BR. IVDepartamento de Ciencias Biologicas, Universidade Federal de Sao Paulo (UNIFESP),
Diadema, SP, BR. V Laboratorio de Endocrinologia Molecular e Translacional, Escola Paulista de Medicina, Universidade Federal de Sao Paulo (UNIFESP),
Sao Paulo, SP, BR.
Breithaupt-Faloppa AC, Correia CJ, Prado CM, Stilhano RS, Ureshino RP, Moreira LFP. 17b-Estradiol, a potential ally to alleviate SARS-CoV-2 infection.
Clinics. 2020;75:e1980
*Corresponding author. E-mail: ana.breithaupt@hc.fm.usp.br
Considering that female sexual hormones may modulate the inflammatory response and also exhibit direct
effects on the cells of the immune system, herein, we intend to discuss the sex differences and the role of
estradiol in modulating the lung and systemic inflammatory response, focusing on its possible application as a
treatment modality for SARS-CoV-2 patients. COVID-19 patients develop severe hypoxemia early in the course of
the disease, which is silent most of the time. Small fibrinous thrombi in pulmonary arterioles and a tumefaction
of endothelial were observed in the autopsies of fatal COVID-19 cases. Studies showed that the viral infection
induces a vascular process in the lung, which included vasodilation and endothelial dysfunction. Further, the
proportions of CD4+ T and CD8+ T lymphocytes were strongly reduced in patients with severe SARS-CoV-2
infection. Estradiol is connected with CD4+ T cell numbers and increases T-reg cell populations, affecting
immune responses to infection. It is known that estradiol exerts a protective effect on endothelial function,
activating the generation of nitric oxide (NO) via endothelial nitric oxide synthase. Estrogen attenuates the
vasoconstrictor response to various stimuli and induces vasodilation in the pulmonary vasculature during stress
situations like hypoxia. It exerts a variety of rapid actions, which are initiated after its coupling with membrane
receptors, which in turn, may positively modulate vascular responses in pulmonary disease and help to maintain
microvascular flow. Direct and indirect mechanisms underlying the effects of estradiol were investigated, and
the results point to a possible protective effect of estradiol against COVID-19, indicating that it may be
considered as an adjuvant therapeutic element for the treatment of patients affected by the novel coronavirus.
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’ INTRODUCTION
Severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2), a novel coronavirus, is responsible for the pandemic
viral disease outbreak that originated in Wuhan, China, in
December 2019. The disease is characterized by severe acute
respiratory syndrome, and the virus has already infected
more than 3 million people worldwide. No therapies have
been shown to be effective to date (1). Data regarding the
clinical management of the disease have been published,
some of which have demonstrated that there are differences
in prevalence and mortality regarding sex (2-4). There is a
higher predominance of men affected in several countries (5);
in Italy, a prevalence of 70% of men among deceased people
was reported (6). Recent data reported by the New York City
Department of Health and Mental Hygiene (7) confirmed
the higher prevalence and mortality of the disease in men.
Moreover, a study of nine pregnant women infected with
SARS-CoV-2 showed that the infection did not evolve to severe
coronavirus disease 2019 (COVID-19) during the pregnancy (8).
Although there is evidence that the immune response
(innate and adaptive) differs between men and women,
sexual dimorphism does not receive deserved attention as a
potential factor for understanding the different immune
responses observed between men and women (9,10). In fact,
clinical studies show that women have a lower incidence
of pneumonia, sepsis, and multiple organ failure than men
(11-13). There are several reports on the participation of
female sex hormones in mediating the repercussions caused
by trauma followed by hemorrhagic shock (14-23). Important
differences exist in epidemiology, pathophysiology, and
treatment of cardiovascular diseases, such as coronary artery
disease, hypertension, cardiomyopathy, and heart failure.
Cardiovascular disorders are also more severe in postmeno-
pausal women (24).DOI: 10.6061/clinics/2020/e1980
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Suba (25) revealed that epidemiological data from SARS
and MERS CoV epidemics indicated that the outcome
of human coronavirus infections is strongly sex-dependent,
suggesting the role of a strong protective estrogen signal
in adult female patients compared to age-matched males.
In this context, considering that female sexual hormones may
modulate the inflammatory response and also exhibit direct
effects on the cells of the immune system, here we intend
to discuss the sex differences and the role of estradiol in
modulating the lung and the systemic inflammatory
response and its possible application as a treatment for
SARS-CoV-2 patients.
The effects of SARS-CoV-2
The inflammatory response is a natural defense mechan-
ism of the body to remove harmful stimuli such as pathogens
and initiate the recovery process. SARS-CoV-2, the new
coronavirus that induces COVID-19, enters the body through
the interaction between the S protein on the virus surface and
angiotensin-converting enzyme-2 (ACE-2) molecules expressed
in epithelial cells in the lungs (26). After SARS-CoV-2
replication in the respiratory and intestinal epithelium cells
(27), it can induce an immune response that causes several
alterations in the lung including inflammation and respira-
tory failure. The binding of the COVID-19 protein to ACE-2
has been shown to downregulate its enzymatic activity and
decrease angiotensin production (28). This mechanism may
be involved in the pathogenesis of pulmonary hypertension
and insufficiency caused by SARS-CoV-2 infection (29).
The inflammatory process is accompanied by the activa-
tion of the coagulation system, which is characterized by the
interaction of coagulation factors, and as observed in severe
cases of sepsis, could lead to a disseminated intravascular
coagulation process. As recent studies described, COVID-19 is
commonly complicated with coagulopathy, and disseminated
intravascular coagulation (DIC) may exist in the majority of
deaths. In addition to pulmonary pneumonia and inflamma-
tion, the presence of vascular dysfunction and thrombosis
have been noted in severe COVID-19 patients (30-32).
Because ACE-2, the receptor necessary for virus uptake, is
expressed in the cardiovascular system (33), it is expected
that this tissue is also susceptible to SARS-CoV-2 infection.
Some new studies showed that COVID induces a vascular
process in the lung, which includes vasodilation and
endothelial dysfunction (34). In this regard, Caruso et al.
(35) observed subsegmental vascular enlargement via com-
puter tomography of patients with COVID-19. The presence
of thrombosis or acute pulmonary embolism in COVID-19
patients associated with increased respiratory dead space
was also reported by Chen et al. (36).
Similar to the disease caused by SARS-CoV identified
in 2002, pulmonary involvement is the dominant clinical
feature observed in COVID-19. Zhang et al. (30) observed the
presence of Rp3 NP SARS-CoV-2 protein in alveolar epithe-
lium cells, including those that were peeled and injured in
the alveolar space in lung biopsies. These authors also
observed diffuse alveolar damage, epithelial cells peeling
with type II reactive hyperplasia of pneumocytes, and fibri-
nous exudate associated with interstitial fibrosis and chronic
inflammatory infiltrate.
Radiological findings in SARS-CoV-2-infected patients
have been well-reported in several articles, and the con-
sensus is that COVID-19 induces pneumonia with bilateral
lung involvement and ground-glass opacity, the latter
being one of the most important radiological characteristic
of COVID-19 that can be present even in asymptomatic
patients (30,37-39).
According to Mason (40), the pathogenesis of COVID-19
can be divided into three stages. The first asymptomatic
phase occurs when the inhaled virus SARS-CoV-2 starts to
replicate in the epithelial cells in the nasal cavity. The second
phase occurs when the virus migrates through the lung and a
more vigorous innate immune response is triggered. The last
phase is manifested by hypoxia, ground glass infiltrate, and
progression to respiratory failure. A range of 20% to 30% of
infected patients will progress to stage 3 of the disease and
will develop pulmonary infiltrates that can also evolve into
acute respiratory distress syndrome (ARDS). ARDS is an
acute inflammatory lung injury, characterized by increased
pulmonary vascular permeability, enlarged lung weight, and
loss of aerated lung tissue (41). ARDS in its most severe form
presents with intense pulmonary inflammation where there
is severe hypoxemia (42). In terms of diagnosis, ARDS is
characterized by a Pa02/Fi02 ratio equal to or less than 200
mmHg. In essence, the mechanisms underlying the trigger-
ing of ARDS are limited to damage to the alveolar epithelium
and capillary endothelium (43,44). There is activation of
neutrophils and high levels of proinflammatory cytokine
release as well as activation of M1-like macrophages and
reactive oxygen and nitrogen species. The incidence of ARDS
is higher in older patients (45), and aging of the lungs may
contribute to the higher mortality rate due to SARS-CoV-2 in
elderly and immunosuppressed individuals.
The severe form of COVD-19 is well-characterized by
dyspnea, hypoxemia, and pulmonary tissue damage. In
addition, 67–85% of critically ill patients admitted to the
intensive care unit (ICU) with COVID-19 will develop ARDS,
and this will be the cause of death (46,47). Huang et al. (46)
reported that dyspnea and lymphopenia was present in
more than 50% of infected patients, and all of them showed
abnormal findings on a chest CT scan. Considering the
inflammatory responses, Lagunas-Rangel et al. (48) sug-
gested that patients with severe COVID-19 show a cytokine
storm with acute increased levels of IL-2, IL-7, G-CSF,
CXCL10, MCP-1, MIP-1a, TNF-a, and IL-6, similar to
patients diagnosed with SARS and MERS. Thus, this
suggests that mortality could be due to viral hyperinflam-
mation that exacerbates lung damage.
Some evidence associated high IL-6 levels with the severity
and mortality of COVID-19 (49,50), although the levels of
interferon (IFN)-g tend to be somewhat decreased in severe
cases compared with moderate cases. These cytokines are
also increased in both the serum and bronchoalveolar
lavage as well as in lung tissue from ARDS patients (51-53).
This alteration in inflammatory response observed in
COVID-19 patients could be associated with a reduction
in CD4+, CD8+, and NK lymphocytes (36). In this regard,
CD4+ T and CD8+ T were strongly reduced in patients
with severe COVID-19 compared with those in patients
with mild disease (54).
Sex differences in immune response and
inflammation
Steroid sex hormones may affect the strength of immune
responses in opposite directions and result in a general dif-
ference between males and females, with stronger immune
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responses in females than in males (for review see Roved
et al. (10)). The dominant profile of the immune response
may be dependent on hormonal variation during the
female sexual cycle. Data indicate that female sex hormones
enhance Th2 immune responses and reduce Th1, and this
influence has been comprehensively covered in many
reviews (9,55,56). Females seems to develop stronger cell-
dependent and humoral responses to infection and vaccina-
tion. The result of these differences can be observed when
comparing the incidence of autoimmune diseases between
sexes (57), which is higher in females, and also by the
observation of higher incidence of sepsis in males in parallel
with higher plasma levels of Th1 cytokines (58-60). Also,
the incidence of sepsis in postmenopausal women increases
to levels almost equal to those seen in age-matched men (61).
In addition to hormonal influences, there is an apparent
genetic disparity, since females carry two inherently poly-
morphic X chromosomes, while males have only one
polymorphic X chromosome passed from the mother. The
random process of X-chromosome inactivation provides
females with a broader panel of proteins and enlarges the
potential diversity of cell populations (9).
In women, the CD4+ T cell numbers are higher (62), and
the ovarian cycle also influences the T reg cell populations
with an increased number when estradiol levels are higher
(63). These differences are connected to estradiol influence
and affect immune responses to infection. In addition,
estradiol exerts anti-inflammatory effects on innate immune
responses by reducing monocyte and macrophage inflam-
matory cytokine release (64), delaying neutrophil apoptosis
and enhancing neutrophil annexin-1 expression without
increasing their activation (65,66). Experimental data confirm
that the leukocyte function in females is more efficient than
that in males, detecting and eliminating pathogens more
rapidly, and that females have higher numbers of tissue
macrophages with a greater density of toll-like receptors;
female macrophage phagocytosis is more efficient with
NADPH oxidase killing, in parallel with an increased popu-
lation of resident anti-inflammatory T-lymphocytes (67). The
dendritic cell population is also influenced by female sex
hormones, with estradiol signaling via estrogen receptor a
ER-a to increase the number of new DCs during inflamma-
tion (68). In plasmacytoid dendritic cells, which are mostly
involved in antiviral responses, estrogen increases the release
of type 1 cytokines that are important for an efficient type 1
immune response (69). The action of estradiol via ER-a also
promotes activation of type 1 INF-inducible innate path-
ways, and the IFN pathway genes are highly expressed in
females, regulating innate immunity (55).
Considering lung inflammation, mortality in ARDS is
higher in males compared to females (70,71). In the respi-
ratory system, sex steroids have been demonstrated to play
important roles in the development and maturation of lungs
and maintenance of normal lung function (72), and sexual
dimorphism impacts the prevalence and incidence of several
lung diseases (73). Sex differences were identified in lung
physiology and disease and have been studied in animal
models. Sex also influences lung development and disease
conditions (74). Sex hormones may contribute to the disease
pathophysiology or serve as protective factors, depending on
the disease involved. Women may be protected from certain
age-related biological processes by producing lower levels of
reactive oxidant species, important drivers of pathology in
age-related pulmonary disease (75). Pulmonary diseases in
women are influenced by age because of the variation of
their level of estrogen. Increasing age is associated with
higher levels of circulating inflammatory mediators and acute
phase proteins. The reduction of estrogen, the increased fat
tissue, and the presence of subclinical infections contribute
to the proinflammatory status of postmenopausal women.
The development and progression of age-related diseases is
dependent on mechanisms associated with cellular senes-
cence that may be triggered by telomere shortening, which
in women occurs at a slower rate than in men (76).
Substantial evidence supports the anti-inflammatory role
of systemic estrogens. The mechanisms behind the female
protection from infection are reported to be mediated mainly
by sex hormones, in particular 17b-estradiol, that can directly
influence synthesis and signal transduction of multiple
cytokines in vitro (67).
17b-estradiol therapeutic effects in
experimental models
Experimental investigations of several disease models
confirm that higher levels of systemic estrogens promote
anti-inflammatory responses. 17-b-estradiol is the predomi-
nant estrogen during the reproductive years, both in its
total serum concentration and in overall estrogenic activity.
Estradiol down-regulates immune functions in endothelial
cells, including the stimulation of leukocyte adhesion and
migration to infected tissues (77-79). It is known that
estrogen plays a protective role in endothelial function (80),
activating the generation of nitric oxide (NO) via endothelial
nitric oxide synthase (eNOS), which is mediated by mecha-
nisms that lead to an increase in NO bioavailability through
the induction of gene transcription and activation of eNOS
via phosphatidylinositol-3-kinase/serine-threonine kinase
(PI3K/AKT) (81). Still, studies by our group using an aortic
occlusion model in male rats indicate that previous treat-
ment with estradiol has a beneficial effect on the course
of mesenteric ischemia and intestinal injury, preventing
mortality due to systemic inflammation (82). Additionally,
in an intestinal ischemia and reperfusion (I/R) model, results
indicate that female sex hormones, notably estradiol, exert
a protective effect on preventing/reducing lung and intest-
inal injuries caused by systemic inflammation after ische-
mic trauma (83-85). Proestrus or estradiol-treated females
showed reduced lung damage and inflammation in ische-
mia and reperfusion models (86,87) and in a hemorrhagic
shock model (88). In addition, treatment with estradiol
showed anti-inflammatory action similar to that of glucocorti-
coids, with reduced expression of transcription factors
involved in the inflammatory response and reduced recruit-
ment of neutrophils by decreasing the production of inter-
leukins, such as IL-8, in addition to chemokines and adhesion
molecules (66,89).
Evidence from clinical and experimental studies strongly
suggests that estrogens can modulate lung inflammation and
allergic reactions, because activation of estrogen receptors
modulates immune cells and both innate and adaptive
immune responses (55,73). However, the effects of estradiol
as a pro or anti-inflammatory factor seem to be dependent on
the pathogenesis of the diseases studied. Estradiol plays a
critical role in improving outcomes in the settings of trauma,
shock, sepsis, myocardial ischemia/reperfusion, and acute
lung injury (ALI). Experimental data with an intestinal I/R
model show that estradiol treatment in ovariectomized
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females reduces lung inflammation and exerts these effects
by modulating eNOS protein expression in the lungs (83). As
permeability edema represents a life-threatening complica-
tion of ALI, estradiol effects on the control of lung vascular
permeability could be considered among the therapeutic
strategies to reduce lung edema (83). In this model, the
inflammatory status of the lungs in ovariectomized females
remains for a long period after the mesenteric reperfusion
has been reestablished and is characterized by the release
of proinflammatory mediators and danger signals. The
treatment with estradiol is able to downregulate the lung
inflammation and its capacity for releasing cytokines (90). In
males, using the same I/R model, estradiol treatment was
effective in reducing lung inflammation even at 1h after the
reestablishment of intestinal perfusion (84). Thus, the effects
of estradiol are important in the modulation of an already
established lung inflammatory response. It is noteworthy to
point out that the proposed treatment was acute and could
be considered a clinical alternative.
Estrogen attenuates the vasoconstrictor response to var-
ious stimuli and induces vasodilation in the pulmonary
vasculature during stress situations like hypoxia (91). This
is mediated by increased levels of prostacyclin and NO as
well as decreased levels of endothelin-1 (ET-1). It is well-
established that estradiol exerts important vasoactive effects
by activation of eNOS, as well as modulation of vasoactive
substances released from endothelial cells or the direct
vasodilation effect via relaxation of smooth muscle cells
(92). The vasoactive effects of ET-1 can be influenced by
estradiol and are organ-dependent (93), and estradiol and its
metabolites inhibit ET-1 synthesis (94). Ovariectomized
female rats present higher ET-1, and estradiol replacement
reduces ET-1 peptide expression (95). Thus, estradiol acts as a
protective vasoactive agent against deleterious microcircula-
tory conditions, such as brain death and ischemia/reperfu-
sion injury (82,96). Brain-dead rats treated with 17b-estradiol
exhibit reduced lung injury, mainly because of its actions on
endothelial and inducible nitric oxide synthase (iNOS) (96).
Regarding injury, estrogen can inhibit vascular responses
and thus prevent proatherosclerotic events (97). The main-
tenance of organ homeostasis depends on a complex net-
work of systems, and reduction of blood flow may have
profound consequences on organ status. Microcirculatory
function following trauma can be affected by sex hormones
(98), altering tissue perfusion and influencing inflammatory
processes. Estrogen exerts a variety of rapid actions, initiated
after coupling with membrane receptors, which may posi-
tively modulate vascular responses in pulmonary disease
and help to maintain microvascular flow.
COVID-19, coagulation, and estradiol influence
Although one of the consequences of severe COVID-19
is the development of ARDS, some studies indicated that
respiratory phenotypes induced by COVID-19 are slightly
different from those classical phenotypes observed in ARDS
patients (99). COVID-19 patients developed a severe hypo-
xemia early in the course of the disease, which is silent most
of the time (100). Most recently, small fibrinous thrombi in
small pulmonary arterioles and a tumefaction of endothelial
were observed in autopsies in cases of fatal COVID-19 (101).
This could indicate the activation of the coagulation cascade
in these patients. In addition, they also reported diffuse
alveolar damage with intense epithelial viral cytopathic
effects both in the alveolar and small airways. More
interestingly, the presence of thrombus occurred in both
damaged and preserved lung parenchyma areas. All together,
these features suggested that anticoagulant drugs could have
beneficial effects in COVID-19 patients.
Estrogen reduces platelet aggregation, the opposite effect
of testosterone (102,103). Notelovitz et al. (104) studied the
short-term effects of estrogens on the coagulation-fibrinolysis
process in surgically treated women, and the results did
not show abnormal or thrombogenic changes in coagulation
parameters. In vitro, 17b-estradiol is able to inhibit plate-
let aggregation by promoting Ca2+ extrusion or reuptake
activity, and its action is dependent on the increase of NO
synthesis (105). Platelet reactivity plays a pivotal role in
thrombus formation, and in vitro data suggest that although
women have a higher magnitude of platelet reactivity, their
response to aspirin is similar or even larger compared to that
of men (106). Experimental data show that a chronic high
physiologic level of estrogen equivalent to that observed in
pregnant mice had a significant inhibitory effect on platelet
aggregation (107). Estrogen mediates beneficial effects on the
cerebral microcirculation and moderated cerebral thrombotic
mechanisms by enhancing the plasma levels of NO (108).
Moreover, estrogens exert positive effects on the pulmonary
vasculature by increasing prostacyclin release and NO
production by eNOS (109). Cowman et al. (110) evidenced
a connection between age and decreases in platelet tracks,
platelet translocation, and unstable platelet interactions. The
altered platelet function associated with aging was more
profound in females compared with that of males and could
be a result of a reduction in estrogen levels in women.
The role of estrogen and estrogen-related
compounds in antiviral mechanism activity
Considering virus-induced lung inflammation, the exces-
sive inflammation leads to tissue damage. In this regard,
T cells seems to be reduced in COVID-19 patients, and the
present T cells seemed to be functionally exhausted (111).
Severe COVID-19 can induce ARDS in more than 50% of
patients, and neutrophils are considered to be the central
cells involved in the pathogenesis of ARDS. Infected female
mice that were administered estradiol showed pulmonary
recruitment of neutrophils and virus-specific CD8 T cells,
releasing more INF-g and TNF-a (112). Moreover, exogenous
estrogen treatment in female mice infected with H1N1
reduced total pulmonary inflammation and the levels of
pro-inflammatory genes in the lung (113).
Many viruses are affected by estrogen at the molecular
level, specifically in the replication machinery and matura-
tion of the virion, but to date, no evidence has been
presented for SARS-CoV-2. Despite the well-known role of
estrogen in inflammation to combat pathogens and infec-
tions, it has been shown that estrogen receptors participate in
repressing transcription virus genes. One example is the
hepatitis B virus (HBV) infection, where ER-a interferes with
virus gene expression through (HNF)-4a (hepatocyte nuclear
factor 4a) binding to HBV enhancer I in hepatocytes (114). In
the hepatitis C virus (HCV) infection model in vitro (Huh7
cells), 17b-estradiol reduced virus infection by interfering
with assembly and/or virus release, disrupting the virus life
cycle, and this effect was inhibited by anti-estrogen Fulves-
trant (115). Moreover, HCV-infected women, after postme-
nopause, exhibit a reduced response to antiviral therapy and
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greater incidence of hepatic fibrosis and hepatic carcinoma
(116,117).
Nevertheless, the most likely antiviral effects of estrogen
are mediated by inflammation modulation. Regarding the
cells that participate in the immune response, dendritic cells
play a crucial role. Escribese et al. (118) infected dendritic
cells with Newcastle disease virus (NDV) and treated the
cells with 17b-estradiol. The authors observed a diminished
type I IFN synthesis, also reducing the CD4 T cell response,
suggesting that estrogen has an antiviral activity on RNA
viruses.
According to the evidence that female sex hormones
exert antiviral activity in many organs, the use of selective
estrogen receptor modulators (SERMs) has been extensively
explored in experimental systems to reduce virus infections
(reviewed by Montoya & Krysan, (119)). In general, SERMs
have been used for several therapeutic purposes, such as in
the treatment for infertility and osteoporosis, but are mainly
related to cancer as adjuvants in chemotherapy, such as
tamoxifen. In viral infection, this compound was suggested
to be considered as an antiviral therapy, because of its
properties of disrupting viral replication during HIV (human
immunodeficiency virus) infection in monocytes and CD4+
T-lymphocyte cell lines (120). Tamoxifen has also displayed
a capacity to inhibit HCV replication via estrogen receptor
assembly to RNA-dependent RNA polymerase NS5B
(121,122). Murakami et al. (122) showed that various SERMs
reduce the production of HCV RNA, preferentially related
to the extracellular but also intracellular virus proteins,
suggesting that SERMs may be a multi-targeted drug that
interferes with several processes, comprising virus entry and
replication.
Of note, the most approximate model of SARS-CoV-2
viral infection is found in MERS-CoV and SARS-CoV. Both
have been demonstrated to be affected by toremifene citrate
(a classical SERM), which delayed virus infection due to the
inhibition of the late endosome virus trafficking (123),
and a similar effect was observed previously with Ebola
virus infection (124). In addition, both in vitro and in vivo
experiments showed that toremifene and clomifene present
antiviral activity against a large variety of Ebola virus
strains (125,126). Importantly, it was also demonstrated that
SERMs can elevate the survival rate of infected animals
by 90% and 50% when using clomifene and toremifene,
respectively. Mechanistically, it has been proposed that
toremifen could target envelope proteins GP1 and GP2,
which permit the viral attachment and access to host cells,
decreasing its stability and resulting in reduced endolyso-
somal membrane fusion (127). This may be considered
good evidence to support that estrogen and estrogen-
related compounds play a major role in antiviral therapies
for SARS-CoV-2.
’ CONCLUSION
Abundant literature highlights sex differences in immune
response and its influence on the incidence and severity
of diseases. Considering trauma, shock, and infection, the
female sex is associated with advantageous outcomes.
Since the hormonal context exerts an important influence
on the homeostasis control and the defense mechanisms,
it is important to consider the beneficial effects of estrogens
with regard to providing better control of defense and the
different immune cells involved, in addition to cardiovas-
cular system protection and flow maintenance. Direct and
indirect mechanisms underlying the effects of estradiol
were investigated, and the results point to a possible positive
effect of estradiol as an adjuvant therapeutic element for
the treatment of patients affected by the novel coronavirus,
SARS-CoV-2 (Figure 1). Studies are being carried out in order
to analyze the effects estradiol on SARS-CoV-2 in vitro, and in
parallel, there is already a clinical trial in course.
Figure 1 - Effects of 17b-estradiol in different compartments/systems.
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